More specifically, it is a direct inhibitor of factor Xa; a factor that in the coagulation process plays a key role in the formation of thrombin (or factor IIa), necessary for the development of the blood clot or thrombus.
The use of apixaban, therefore, is indicated in specific cases where it is necessary to prevent blood clotting. In order to carry out its action, this active principle must be administered orally; in fact, the drugs that contain it are in the form of coated tablets.
Currently, the only apixaban-based medicine marketed in Italy is Eliquis. It is a drug in band A whose cost, therefore, can be reimbursed by the National Health System (SSN). However, its dispensing can only take place upon presentation of a specific limitative repeatable medical prescription (RRL); this means that it can be sold to the public only on prescription from hospitals or specialists.
